Sanofi, Babylon link-up to tackle digestive health
Only an estimated 30% of people in the UK who suffer from IBS have actually been diagnosed and, of those, 61% often mistreat their symptoms with analgesics or antacids.
Read More
Tag: IBS
New at-home test to give fresh insight into IBS
The trial is in the midst of recruiting over 400 patients aged 18-75 years old.
Read More
EU approves Truberzi for IBS-D
European regulators have issued a green light for Allergan’s Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhoea (IBS-D).
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
